



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91 731-429 4567 Fax No. : +91 730-429 4444

Date:-14th August, 2024

Email : mail@alpalabs.in

CIN : L85195MP1988PLC004446

The Bombay Stock Exchange
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Scrip Code:532878

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E)

Mumbai – 400 051

Scrip Code:ALPA

Dear Sir/Madam,

Sub: Revision of Consolidated financial Results.

Sir/Madam,

We are writing to bring to your attention an inadvertent typographical error identified in the consolidated financial results of our company for the quarter ended June, 2024, which were submitted on 13th August, 2024.

Upon review, we have discovered that the comparative quarter of June 2023 of consolidated results was not correct and we assure you that this was an unintentional oversight, and we deeply regret any inconvenience this may have caused.

In accordance with the applicable regulations, we hereby submit the revised consolidated financial results for the quarter ended June, 2024, correcting the aforementioned error. Please find enclosed the corrected consolidated financial statements along with the required disclosures.

We request you to kindly take the revised consolidated financial results on record and replace the previously submitted erroneous results. We also confirm that apart from this correction, there are no other changes in the financial results as compared to the results submitted earlier.

We sincerely apologize for this oversight and thank you for your understanding and cooperation in this matter.

Thanking you,

Yours faithfully,

For ALPA LABORATORIES LIMITED


Swati Bagh
Company Secretary



ALPA LABORATORIES LIMITED

Financial Results for Quarter ended 30th June 2024

33/2 PIGDAMBER, A.B. ROAD,
RAU INDORE (M.P.) 453446
(Rs. in lacs except EPS)

II. Statement of Profit and Loss - Consolidated				
Particulars	Consolidated Results			
	Quarter Ended			Year Ended
	Jun-24	Mar-24	Jun-23	Mar-24
	Unaudited	Audited	Unaudited	Audited
1. Income				
a) Revenue from operations	2,144.37	2,360.66	2,542.96	10,873.90
b) Other Income	516.02	396.53	443.92	1,488.97
Total income from operations	2,660.38	2,757.19	2,986.88	12,362.87
2. Expenses				
a) Cost of materials consumed	1,421.90	929.19	1,716.10	6,287.91
b) Purchases of stock-in-trade	19.12	232.88	116.93	579.75
c) Changes in inventories of finished products, work in progress and stock in trade	(66.71)	(107.86)	197.16	(64.12)
d) Employee benefit expenses	332.15	387.33	297.01	1,329.05
e) Finance costs	5.17	29.44	1.70	35.92
f) Depreciation and amortization expense	54.28	52.47	27.55	195.49
g) Other expenses				
Manufacturing & Operating	128.36	190.49	142.69	656.87
Others	256.49	377.91	187.28	1,273.80
Total expenses	2,150.76	2,091.85	2,686.42	10,294.67
3. Profit/(Loss) before exceptional items and tax (1-2)	509.62	665.34	300.46	2,068.20
4. Exceptional Items	-	(1.78)	(2.84)	-
5. Profit/ Loss(-) before tax (3+/-4)	509.62	667.12	303.30	2,068.20
6. Tax (Expenses)/ Benefit				
Current tax	-	(300.00)	-	(300.00)
Deferred Tax	-	(11.30)	-	(11.30)
Tax Related to Earlier Years	-	(0.51)	-	(79.25)
7. Profit/ Loss(-) for the period (5-/+6)	509.62	355.31	303.30	1,677.65
8. Other Comprehensive Income				
(i) (a) Items that will not be reclassified to profit or loss	(0.26)	3.58	-	8.16
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	(0.26)	3.58	-	8.16
9. Total comprehensive income for the period	509.36	358.89	303.30	1,685.81
10. Paid-up equity share capital (Face Value Rs. 10 Each)	2,104.06	2,104.06	2,104.06	2,104.06
11. Other equity (excluding revaluation reserve)				13,086.90
12. Debenture Redemption Reserve				
13. Basic and Diluted Earnings per share after extraordinary items (not annualized)	2.42	1.71	1.44	8.01

Notes -

1. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting Rules, 2016

2. The Company is operating in the single segment of Drugs & Chemicals.

3. The Figures of Previous Year/ Periods may have been regrouped/reclassified/restated wherever necessary.

4. Other Income for the quarter includes unrealized profit occurred on account of increase in fair market value of the investments.

Place: Indore

Date: August 13, 2024



By order of the board
For Alpa Laboratories Limited

Mahendra
Mahendra Singh Chawla
Whole-Time Director